Which scale most accurately measured distress in this study?
🚨 What is Distress in Cancer Care? 🚨
Cancer Distress 😟 is psychological/social/spiritual pain. 1 in 4 (20%)-->up to 80% impacted. Screen it! 🩺 The 6th Vital Sign!
#DistressScreening #PallOnc #TOeJC
doi.org/10.1200/OP.23.00358
This is our first ever OUP eJournal Club! We are anxious to ehear your thoughts on this study.
Absolutely agree — mindfulness-based interventions like #MBCR have shown meaningful benefits for people with cancer. Expanding access, particularly in #LMICs, remains a crucial next step. #TOeJC @OncJournal
@Linda_E_Carlson @AmDTx_official
Susan Bates retweeted
We are thrilled to share a recent publication from @OncJournal Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study
🔗: doi.org/10.1093/oncolo/oyae3… #TOeJC
Susan Bates retweeted
Unraveling the Link: MUTYH mutations drive higher KRAS G12C prevalence, heightened tumor mutational burden, and unique mutational signatures across cancers. @fred_hirsch #MolecularBiology #Research doi.org/10.1093/oncolo/oyad2…
Susan Bates retweeted
Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study buff.ly/3EJmEGI
Susan Bates retweeted
📚 🔬 Thrilled to share a new EORTC publication on @OncJournal:
"#QualityOfLife in Male #BreastCancer: Prospective Study of the International #MaleBreastCancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)"
👉 doi.org/10.1093/oncolo/oyad1…
#CancerResearch #ClinicalTrials #Oncology
Upfront Atezolizumab Poses Lower Risk of Hyperprogression in NSCLC cancertherapyadvisor.com/hom…
@CancerTherAdvsr Thank you for highlighting an important study in The Oncologist showing contexts in which hyperprogression occurs.@OncJournal.
Agree completely. Words matter, and "fail treatment" inevitably implies, however unintended, that the patient is somehow at fault. @OncJournal
This Post is from an account that no longer exists. Learn more
Susan Bates retweeted
Older Patients Are Comfortable With Telehealth and Prefer It as an Option - 92% of those over 70 say they are comfortable with telehealth. buff.ly/3mLB7fU
Susan Bates retweeted
Patients are the greatest educators.
Every interaction with them is a learning experience. Let's continue to learn from their strength, resilience, and unique perspectives.
#patientexperience #education @OncoAlert @CancerDotNet @montypal @DrChoueiri @ASCO @myESMO @KidneyCancer
Exciting news‼️
Our study on FKSI-19 was published in @OncJournal
⚠️Patients rated fatigue, lack of energy & worry as most relevant, while blood in urine, fevers & appetite were least relevant
Thanks @tompowles1 @montypal & committee & @KidneyCancer
academic.oup.com/oncolo/adva…
Susan Bates retweeted
Congratulations to Susan Bates, MD, who has received the 2023 ESMO (@myESMO) Targeted Anticancer Therapies Honorary Award, recognizing her significant contributions to the field of anticancer drug development. 👏
Dr. Bates presents her award lecture today at #ESMOTAT23.
Susan Bates retweeted
Please all send us examples of PD1/L1 post PD/L1 failures from randomized trials where same control backbone in both arms. We need the help of the oncology community ! Thank you @OncBrothers @OncoAlert @ASCO @myESMO @CureMelanoma @SWOG @ALLIANCE_org @eaonc @NCICancerTrials
I remain so grateful to @genentech & @ExelixisInc for allowing us to conduct this study - so vital now that I see rampant use of CPI rechallenge. I remember designing the study with @DrChoueiri as far back as 2015 when @neerajaiims & I started #COSMIC021. As I look around the #oncology space, it is still the cleanest design to answer the question - A vs A+B where B = CPI. Excited to share the full data with the #oncology community later; in the meantime, what examples are there of randomized studies exploring CPI challenge in other cancers? @DrJNaidoo @JackWestMD @GIcancerDoc @YJanjigianMD @FunchainMD @AnaVManana @VivekSubbiah @StephenVLiu @tmprowell @BrainTumorDoc
I am amazed & thrilled to have been selected for this important award, and am looking forward to being in Paris for the 2023 ESMO TAT meeting -- by my count it is TAT #20. Thank you ESMO! #ESMOTAT23
#ESMOTAT23: ESMO is pleased to announce that @susanebates received the 2023 ESMO TAT Honorary Award for her significant contribution to the field of anticancer drug development.
📌esmo.org/newsroom/esmo-socie…
Important commentary on future directions in ctDNA assessment. May be an approach to identifying cancers with epigenetic origins. @OncJournal
🆕Just published. 📰
👇🏾See our editorial @OncJournal 🗞️on #LiquidBiopsies.
“Types of Liquid Biopsies:
Understanding the Different Lenses 🔍Through Which They Can Detect Cancer”
📌academic.oup.com/oncolo/adva…
On work from @mgoudaMD @FilipJankuMD @skopetz.
@OncoAlert
#ctDNA🩸🧬
Susan Bates retweeted
An article from the February issue of @OncJournal reports on whether differences in patients’ race/ethnicity, preferred language, and other factors are associated with patient enrollment in oncology research studies. buff.ly/3m2Ayhd
Susan Bates retweeted
Just in @OncJournal: In a large cohort of Black men with advanced #prostatecancer undergoing ctDNA profiling 👉Machine learning analysis shows ⬆️ frequency of AR, EGFR, MYC, FGFR1, CTNNB1 alterations in Black vs. White men👇bit.ly/3wHKRcM @OncoAlert @PBarataMD @bilenma – at Holladay, UT
Susan Bates retweeted
🔘In this retrospective study
No increase in renal or non-renal immune-related side effects with immunotherapy in patients with stage 4-5 CKD (eGFR<30), which is usually the exclusion criterion in clinical trials
@OncJournal @OncoAlert #MedTwitter @ASCO
doi.org/10.1093/oncolo/oyad0…
Our terrific CTR editor at The Oncologist! @OncJournal
@DocSacher is currently presenting at the @IASLC’s #TTLC23 the topic: Combination IO and targeted Therapy. #LCSM
